Editorial Article
Eleven and a Half Events: The Prescription Stopped Being the Product
Somewhere in 2025, the American prescription quietly stopped being a document and became a session.
The evidence is a ratio almost nobody quotes. In 2024 the Surescripts network exchanged 27.2 billion transactions and filled 2.6 billion electronic prescriptions — 10.46 events for every prescription that reached a pharmacy. In 2025 the network’s transaction count grew 12.3 per cent to 30.5 billion. Prescription volume did not grow at anything like that rate; on the network’s own disclosure it grew in the low single digits. Divide one by the other and you get roughly 11.5 events per prescription, a 10.04 per cent increase in the number of things that happen to a prescription in the space of a year.
That ratio explains a number that otherwise looks wrong. Pheonix Research puts global e-prescribing value at USD 1,940.0 million in 2025, rising to USD 4,340.0 million in 2033 — 10.59 per cent a year — while the count of electronic prescriptions rises from 4,500 million to 6,120 million, or 3.92 per cent. Value is growing two and a half times faster than volume, and no additional patient, prescriber or pharmacy is required to produce the difference. Each prescription simply carries more paid activity than the one before it. Value per e-prescription goes from USD 0.43 to USD 0.71.
The first event is free
Transmission is the most important link in the chain and the least valuable. Set the entire global transmission layer against the entire global prescription count and you get a number under seven cents per prescription — USD 300 million against 4,500 million prescriptions, growing at 5.77 per cent, roughly volume plus a small price effect.
This is not a market failure. It is a market that did its job. In the United States, 84.4 per cent of prescribers who prescribe electronically are enabled to do so for controlled substances and 98.3 per cent of pharmacies can receive them; 1.39 million prescribers used the network in 2025, up 4.0 per cent. In England, 1.16 billion of the 1.19 billion items dispensed in 2025/26 — 97 per cent — went through the Electronic Prescription Service. Transmission was subsidised into existence by policy, standardised by NCPDP, and is now a utility priced accordingly. Nobody is getting paid for the first event any more.
The tenth event is the business
What people are paying for is what happens around the order. Real-Time Prescription Benefit returned 1 billion responses to 973,463 prescribers in 2025, finding patients an average of USD 77 per prescription in savings, and USD 817 on a specialty prescription. Eligibility informed 5.07 billion care events. Prior-authorisation automation held its median approval at 18 seconds across 83 medications, up from 40 the year before, with a 34 per cent automated approval rate for in-scope drugs and prescriber abandonment collapsing from 22 per cent to 4 per cent.
Not one of those is a transmission revenue. All of them are billed per event, per response, per transaction, to a buyer who is often not the prescriber — a PBM, a plan, a patient-access programme. That is why the layer split moves the way it does. Transmission and prescriber-side software carry 48.5 per cent of 2025 value and 34.1 per cent of 2033 value. Benefit and price intelligence plus prior authorisation carry 39.2 per cent and then 55.1 per cent.
This inverts the pharmacy next door
It is worth holding this against what is happening one layer down, in the pharmacy itself. Our pharmacy automation research found a market growing at 7.76 per cent on unit growth of 4.90 per cent, and the reason was scarcity: nearly eight thousand fewer US retail pharmacies than in 2018, while dispensing revenue hit a record. Automation was being sold into a shrinking base of surviving sites, so revenue per installation had to rise.
E-prescribing has the opposite problem. There is no scarcity of prescriptions — there are 4.5 billion of them a year and the number is climbing. There is no scarcity of prescribers, no scarcity of pharmacies, and no scarcity of transmission capacity. Abundance at the bottom of the stack is precisely why the value had to migrate upward, to the only genuinely scarce thing in the process: the decision about which drug, at what cost, covered by whom, approved by when.
What this means if you sell into it
Two strategic conclusions follow, and they are uncomfortable for anyone whose product is the prescribing screen.
The first is that attachment beats distribution. Reaching 98 per cent of US e-prescribers through enabled EHRs did not make real-time benefit an expensive product; it made it a feature that every platform can claim. The capabilities that hold price are the ones that keep adding decisions a platform cannot make alone — specialty authorisation, therapeutic alternatives, cross-border resolution, the fill signal that tells you a patient never collected the drug.
The second is that the platform vendors hold the strongest hand and know it. Epic, Oracle Health, athenahealth and MEDITECH own the surface where prescribing happens. Any decision-layer capability that proves it can be priced becomes a candidate for absorption, because a platform can bundle it at zero marginal cost to defend its own workflow. The reason prior authorisation is the safest of the decision layers is that half of it lives outside the platform: the payer’s determination criteria sit with the payer, and a platform cannot absorb what it does not own.
What would break the argument
The premium is the fragile part, and it is worth being precise about how fragile. If value per e-prescription grows at 4 per cent instead of 6.42 per cent — because buyers refuse to pay separately for events that arrive inside a platform they have already bought — then 2033 lands at about USD 3,611.3 million rather than USD 4,340.0 million. If prior authorisation grows at 12 per cent rather than 18.53 per cent, 2033 lands at about USD 3,622.0 million. Both failures converge near USD 3.6 billion.
Note what does not move in either case: the prescription count. This market is not going to have a volume problem. It is going to have a pricing argument, conducted inside renewals, between platforms that want the decision layers bundled and specialists that need them itemised. Eleven and a half events per prescription is the size of the argument.
Figures in this article are drawn from the Global E-Prescribing Market Report 2026–2033, built from Surescripts network disclosure, the NHS Business Services Authority’s General Pharmaceutical Services release, CMS rulemaking and EU regulation. No competitor research is cited.
Frequently Asked Questions
What does "11.5 events per prescription" actually measure?
It is the ratio of network transactions to prescriptions filled. Surescripts exchanged 27.2 billion transactions and filled 2.6 billion e-prescriptions in 2024 — 10.46 events per prescription. In 2025 transactions grew 12.3 per cent to 30.5 billion while prescription volume grew in the low single digits, taking the ratio to roughly 11.5. The extra events are benefit checks, real-time price responses, prior-authorisation requests, medication-history lookups and clinical document links.
Why is e-prescribing value growing faster than prescription volume?
Because revenue per prescription is rising. Pheonix Research models value per e-prescription at USD 0.43 in 2025 and USD 0.71 in 2033, a 6.42 per cent annual increase, on top of 3.92 per cent volume growth — giving 10.59 per cent market growth from USD 1,940.0 million to USD 4,340.0 million. The growth comes from pricing the decision layers, not from converting more paper prescriptions.
Is e-prescribing still an adoption story?
No. 84.4 per cent of US e-prescribers are enabled for controlled substances and 98.3 per cent of pharmacies can receive them; 1.39 million prescribers used the network in 2025, up 4.0 per cent. In England 97 per cent of dispensed items moved through the Electronic Prescription Service. There is almost no adoption left at the transmission layer, which is why that layer grows at 5.77 per cent and loses share every year.
Does the market size include pharmacy dispensing systems?
No. The scope covers prescriber-side software, the networks that carry the transaction and the decision services attached to the prescription. It excludes dispensing cabinets, dispensing robots and packaging automation, which are covered in Pheonix Research reports on pharmacy automation systems and smart pill dispensers. That exclusion is why the figure sits below numbers commonly circulated for this market.
